CD274 and non-small cell lung carcinoma: This method will be explored in the forthcoming INDIGO study, which aims to assess the combination of the PD-L1 inhibitor, atezolizumab and of the anti-TIGIT, tiragolumab as a first-line treatment for patients with advanced mTLS-positive PD-L1-low NSCLC.